Key Takeaway: The interim analysis of a safety cohort for a study involving FOLFIRINOX combined with elraglusib and losartan in untreated metastatic pancreatic ductal adenocarcinoma (PDAC) has been presented at the 2024 AACR conference. This combination therapy aims to improve treatment outcomes for patients with PDAC. Early results indicate a favorable safety profile.
Price reaction · baseline $8.02 (2024-09-17 close) · hit pre-market · clean, no other ACTU news in the window
day 0 close · peak
-0.2%
Market Sentiment Analysis
POSITIVE FACTORS
Interim analysis shows promising safety results.
Combination therapy may enhance treatment efficacy.
Focus on metastatic pancreatic ductal adenocarcinoma is critical.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
9.4%
average across 4 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
9-ING-41
Phase 2 · Cancer
Full Press Release Details
2024-AACR- FOLFIRINOX with glycogen synthase kinase-3 beta (GSK-3β) inhibitor elraglusib and transforming growth factor-β (TGFβ) inhibitor losartan in untreated metastatic pancreatic ductal adenocarcinoma (PDAC): interim analysis of safety cohort Download PDF View Resource
Frequently Asked Questions
What is the focus of the interim analysis?
The interim analysis focuses on the safety of FOLFIRINOX combined with elraglusib and losartan in untreated metastatic PDAC.
What are the key components of the therapy studied?
The therapy studied includes FOLFIRINOX, a GSK-3β inhibitor (elraglusib), and a TGF-β inhibitor (losartan).
Where was the analysis presented?
The analysis was presented at the 2024 AACR conference.
What type of cancer is being targeted?
The study targets untreated metastatic pancreatic ductal adenocarcinoma (PDAC).